Epigenomics
Epigenomics H1 Revenues Down 31 Percent
The company attributed the revenue decline to the SARS-CoV-2 pandemic, which has caused patients eligible for its colon cancer test to delay screenings.
In Brief This Week: PerkinElmer, OraSure Technologies, LabCorp, Molzym, UniLabs, and More
News items for the in vitro diagnostics industry for the week of May 10, 2021.
Epigenomics Reports 24 Percent Drop in 2020 Revenues, Seeks Sale After Negative Coverage Decision
The firm said that due to a negative coverage decision and capital constraints, it is evaluating options including a sale by a public takeover or an asset deal.
CMS Finalizes Blood-Based Colon Cancer Screening NCD with Non-Coverage for Epi ProColon
The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.
Epigenomics Issues €5.5M Convertible Bond
The proceeds of the bond are going to support the firm's operations as it awaits a final Medicare coverage decision on its colon cancer test.
Nov 12, 2020
Epigenomics Posts 30 Percent Rise in Q3 Revenues
May 7, 2020
Epigenomics Q1 Revenues Down 28 Percent
Apr 29, 2020
Epigenomics Preliminary Q1 Revenues Drop 33 Percent
Nov 19, 2019
Epigenomics Posts 69 Percent Drop in Q3 Revenues
Aug 7, 2019
Epigenomics Q2 Revenues Slide 25 Percent
May 10, 2019
May 8, 2019
Epigenomics Q1 Revenues Rise 7 Percent
Mar 27, 2019
Epigenomics 2018 Revenues Down 21 Percent
Nov 7, 2018
Epigenomics Posts 57 Percent Rise in Q3 Revenues
May 9, 2018
Epigenomics Posts 10 Percent Q1 Revenue Increase
Mar 23, 2018